Navigation Links
New Rhinosinusitis Clinical Trials Guidance Developed

More than 30 million Americans can attest that rhinosinusitis – an often recurring combination of congestion, discolored nasal discharge//, cough, and headache – seriously affects their quality of life.

A group of 25 physicians from five national medical societies has collaborated to design the first clinical trial guidelines for researchers working to find the most effective treatments for rhinosinusitis.

The U.S. Food and Drug Administration (FDA) has issued specific guidance documents for designing clinical trials of certain diseases, including acute bacterial sinusitis, but there has not been a guidance document put forth for chronic rhinosinusitis clinical trials. “Rhinosinusitis: Developing Guidance for Clinical Trials,” bridges this gap and offers researchers specific recommendations for rhinosinusitis clinical trials pertaining to acute bacterial rhinosinusitis, chronic rhinosinusitis with or without nasal polyps, and allergic fungal rhinosinusitis.

The guidelines will be published in November 2006 in a supplement of the American Academy of Allergy, Asthma and Immunology’s (AAAAI) Journal of Allergy and Clinical Immunology (JACI) and in the American Academy of Otolaryngology – Head and Neck Surgery/Foundation’s (AAO-HNS/F) white journal, Otolaryngology – Head and Neck Surgery. The corresponding author is Eli O. Meltzer, MD, Co-Director, Allergy and Asthma Medical Group and Research Center, San Diego, CA.

“The goal of the Rhinosinusitis Initiative has been to provide researchers with the needed methodologies which will promote better clinical studies that can lead to improved patient care,” Meltzer said.

Key components of the guidance include:
?Reviewing FDA’s role in drug trials.
?Presenting guidance for rhinosinusitis clinical trials of antimicrobials, anti-inflammatory treatment, and symptom reliever or mediator blocker treatments.
?Recommending scoring instruments for symptoms, rad iographs, endoscopic testing, and quality of life assessment.
?Recommending techniques for quantifying microbiologic factors, assessing inflammatory indices, and statistically measuring outcomes.

“Rhinosinusitis: Developing Guidance for Clinical Trials” offers a comprehensive list of rhinosinusitis clinical trial components ranging from the title of the trial, to study design, objectives and safety assessments.

The five societies involved in the collaboration include: the American Academy of Allergy, Asthma and Immunology (AAAAI); the American Academy of Otolaryngic Allergy (AAOA); the American Academy of Otolaryngology – Head and Neck Surgery/Foundation (AAO-HNS/F); the American College of Allergy, Asthma and Immunology (ACAAI); and the American Rhinologic Society (ARS).

This is the group’s second collaboration. Its original document, “Rhinosinusitis: Establishing Definitions for Clinical Research and Patient Care,” was published concurrently in the December 2004 editions of the JACI and OTO-HNS and can be found at The document, which led to “Rhinosinusitis: Developing Guidance for Clinical Trials,” was a catalyst for further research on this disease. The participants in the effort agree that promoting more research on both acute and chronic rhinosinusitis is essential, and a better understanding of the cause of these diseases is needed.


Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
8. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Cancer Clinical Research in India
11. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
Post Your Comments:

(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November ... of patients and their families, shaped my desire to improve the system of care. ...
(Date:11/24/2015)... FL (PRWEB) , ... November 24, 2015 , ... ... and engineer of patented products, announces Innovative Blending, a household invention that revolutionizes ... , "The Juice & Smoothie Bars market is worth $2 billion," says Scott ...
(Date:11/24/2015)... ... 2015 , ... World Patent Marketing , a vertically ... invention which offers a combination of natural essential oils to create something fragrantly ... $3 billion annually," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:11/24/2015)... ... , ... “I am so thrilled, as a newbie here, to leave a mark for the ... School Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching ... longer tenure. , “This is such an amazing school and we deserve a space where ...
(Date:11/24/2015)... ... November 24, 2015 , ... There’s nothing better than giving the gift of ... can enjoy. , This year, gardens are popping up in the most unexpected ... , Vita Gardens’ African Keyhole Garden Bed ($499) , Water conscious gardeners – ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Abaxis, ... manufacturing point-of-care instruments and consumables for the medical, research, ... Taylor , Chief Financial Officer, will present at the ... Tuesday, December 1, 2015 at 11:30 a.m. ET. The ... Palace in New York City . ...
(Date:11/24/2015)... Nov. 24, 2015   Mast Therapeutics, Inc. ... molecular adhesion and sealant technology (MAST) platform to develop ... stroke, today announced that the Company,s Chief Executive Officer, ... Piper Jaffray 27 th Annual Healthcare Conference on ... the New York Palace hotel in New ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Arena Pharmaceuticals, ... scheduled to present a corporate overview and update at the ... December 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. ... New York City . . ... days following the event. Please connect to Arena,s website several ...
Breaking Medicine Technology: